Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $125.68 -3.61 (-2.79%) Closing price 04:00 PM EasternExtended Trading$125.68 0.00 (0.00%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Axsome Therapeutics Stock (NASDAQ:AXSM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Axsome Therapeutics alerts:Sign Up Key Stats Today's Range$123.54▼$130.0050-Day Range$100.39▼$129.2952-Week Range$75.56▼$139.13Volume756,213 shsAverage Volume761,314 shsMarket Capitalization$6.27 billionP/E RatioN/ADividend YieldN/APrice Target$177.86Consensus RatingBuy Company Overview Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes. Axsome’s pipeline includes several late-stage and approved product candidates. AXS-05, a first-in-class oral investigational therapy combining dextromethorphan and bupropion, received U.S. Food and Drug Administration (FDA) approval for the treatment of major depressive disorder in 2021 and for agitation associated with Alzheimer’s disease. AXS-07, a combination of meloxicam and rizatriptan for acute migraine, gained FDA approval in 2023. The company is also advancing AXS-12 for narcolepsy and idiopathic hypersomnia under FDA review, as well as AXS-14, a proprietary formulation of esreboxetine, targeting fibromyalgia and related chronic pain conditions. Founded in 2012 and headquartered in New York City, Axsome Therapeutics conducts its research and development activities primarily in the United States. The company’s leadership team is led by President and Chief Executive Officer Herriot Tabuteau, M.D., who brings extensive experience in neurologic and psychiatric drug development. Under his guidance, Axsome has advanced multiple clinical programs through crucial regulatory milestones and continues to collaborate with academic institutions and contract research organizations to support its growth strategy.AI Generated. May Contain Errors. Read More Axsome Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreAXSM MarketRank™: Axsome Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 72nd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Upside PotentialAxsome Therapeutics has a consensus price target of $177.86, representing about 40.5% upside from its current price of $126.61.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.79) to $2.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -24.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -24.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 107.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.45% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.03 Percentage of Shares Shorted7.45% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News Sentiment1.04 News SentimentAxsome Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Axsome Therapeutics this week, compared to 14 articles on an average week.Search Interest18 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,527,554.00 in company stock.Percentage Held by Insiders22.40% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXSM Stock News HeadlinesMark Saad Sells 9,127 Shares of Axsome Therapeutics (NASDAQ:AXSM) StockSeptember 6 at 8:10 AM | insidertrades.comRoger Jeffs Sells 13,464 Shares of Axsome Therapeutics (NASDAQ:AXSM) StockSeptember 3, 2025 | insidertrades.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 9 at 2:00 AM | Banyan Hill Publishing (Ad)Axsome Therapeutics (NASDAQ:AXSM) Director Roger Jeffs Sells 20,000 SharesAugust 30, 2025 | insidertrades.comInsider Selling: Axsome Therapeutics (NASDAQ:AXSM) Director Sells 16,694 Shares of StockAugust 27, 2025 | insidertrades.comAxsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8 at 5:49 PM | seekingalpha.comAxsome Therapeutics (NASDAQ:AXSM) Upgraded at Wells Fargo & CompanySeptember 5, 2025 | americanbankingnews.comAxsome Therapeutics (AXSM) Has a New Rating from Wells FargoSeptember 4, 2025 | theglobeandmail.comSee More Headlines AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $84.61 at the beginning of the year. Since then, AXSM stock has increased by 49.6% and is now trading at $126.6050. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Monday, August, 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. The business earned $150.04 million during the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 283.22% and a negative net margin of 49.88%. Read the conference call transcript. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.98%), State Street Corp (1.92%), Bank of America Corp DE (1.51%) and Eventide Asset Management LLC (1.45%). Insiders that own company stock include Roger Jeffs, Mark Coleman, Nick Pizzie, Mark E Saad, Mark L Jacobson and Hunter R Murdock. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Marinus Pharmaceuticals (MRNS). Company Calendar Last Earnings8/04/2025Today9/09/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AXSM CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees380Year Founded2012Price Target and Rating Average Price Target for Axsome Therapeutics$177.86 High Price Target$216.00 Low Price Target$150.00 Potential Upside/Downside+42.2%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.22 million Net Margins-49.88% Pretax Margin-50.05% Return on Equity-283.22% Return on Assets-33.06% Debt Debt-to-Equity Ratio1.66 Current Ratio1.57 Quick Ratio1.51 Sales & Book Value Annual Sales$385.69 million Price / Sales16.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book105.98Miscellaneous Outstanding Shares49,900,000Free Float38,723,000Market Cap$6.24 billion OptionableOptionable Beta0.54 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AXSM) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.